Moderna Doubles as mRNA's First Cancer Vaccine Beats Keytruda in Phase 3
Moderna more than doubled Wednesday after its personalized mRNA therapy with Merck's KEYTRUDA met Phase 3 recurrence-free and distant-metastasis endpoints in resected melanoma — the first late-stage win for an mRNA cancer vaccine. Hazard ratios were not disclosed; the $34 billion re-rating is a plat